N@N

ZIOPHARM Oncology to Host Analyst & Institutional Investor Meeting on November 29, 2010

^{Published on 2010-11-15 09:40:18 - Market Wire}
 

NEW YORK--([ BUSINESS WIRE ])--ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that the Company will host an analyst and institutional investor meeting on Monday, November 29, 2010 from 4:30 P.M. to 6:00 P.M. Eastern Time in New York City.

The event will be moderated by Jonathan Lewis, M.D., Ph.D., Chief Executive Officer, of ZIOPHARM and will be comprised of an in-depth panel discussion of the Company's product pipeline and clinical development strategy. The program will include presentations by experts as well as ZIOPHARMa™s management and will be followed by a question and answer session.

The panel will include:

• James O. Armitage, M.D., Joe Shapiro Professor of Medicine, Section of Oncology Hematology, Department of Internal Medicine at University of Nebraska Medical Center
• Susan Knox, M.D., Associate Professor Department of Radiation Oncology, Member of BIO-X and Advising Dean at Stanford University School of Medicine
• Robert Maki, M.D., Ph.D., Immediate past president of the Connective Tissue Oncology Society (CTOS), Co-leader of Adult Sarcoma Disease Management Team at Memorial Sloan-Kettering Cancer Center
• Vincent A. Miller, M.D., Associate Attending Physician, Thoracic Oncology Service, Memorial Sloan-Kettering Cancer Center, Associate Member, MSKCC, Associate Professor of Clinical Medicine, Weill Medical College, Cornell University
• Larry Norton, M.D., Deputy Physician-in-Chief for Breast Cancer Programs, Memorial Sloan-Kettering Cancer Center, Medical Director, Breast Cancer Programs
• Mark Thornton, M.D., Ph.D., President, Sarcoma Foundation of America, President, National Organization Against Rare Cancers

The meeting will be webcast live and may be accessed by visiting the Investor Relations section at [ www.ziopharm.com ]. The webcast will be archived for ninety days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of cancer drugs. The Company is currently focused on three clinical programs.

Palifosfamide (Zymafos^TM or ZIO-201) is a novel DNA cross-linker in class with bendamustine, ifosfamide, and cyclophosphamide. ZIOPHARM is currently enrolling patients in a randomized, double-blinded, placebo-controlled Phase III trial with palifosfamide administered intravenously for the treatment of metastatic soft tissue sarcoma in the front-line setting. The Company expects to initiate additional studies in the near-term, including a Phase I intravenous study of palifosfamide in combination with standard of care addressing small cell lung cancer and a Phase I study of oral palifosfamide.

Darinaparsin (Zinapar^TM or ZIO-101) is a novel mitochondrial-targeted agent (organic arsenic) being developed intravenously for the treatment of peripheral T-cell lymphoma with a pivotal study expected to begin in late 2011. An oral form is in a Phase I trial in solid tumors.

Indibulin (Zybulin^TM or ZIO-301) is a novel, oral tubulin binding agent that is expected to have several potential benefits including oral dosing, application in multi-drug resistant tumors, no neuropathy and minimal overall toxicity. It is currently being studied in Phase I/II in metastatic breast cancer.

ZIOPHARM's operations are located in Boston, MA with an executive office in New York City. Further information about ZIOPHARM may be found at [ www.ziopharm.com ].

ZIOP-G

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements for ZIOPHARM Oncology, Inc. that involve risks and uncertainties that could cause the Company's actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurance that any of the Company's development efforts relating to its product candidates will be successful, or such product candidates will be successfully commercialized. Other risks that affect forward-looking information contained in this press release include the possibility of being unable to obtain regulatory approval of the Company's product candidates, the risk that the results of clinical trials may not support the Company's claims, the risk that pre-clinical or clinical trials will proceed on schedules that are consistent with the Company's current expectations or at all, risks related to the Company's ability to protect its intellectual property and its reliance on third parties to develop its product candidates, risks related to the sufficiency of existing capital reserves to fund continued operations for a particular amount of time and uncertainties regarding the Company's ability to obtain additional financing to support its operations thereafter, as well as other risks regarding the Company that are discussed under the heading "Risk Factors" in the Company's filings with the United States Securities and Exchange Commission. Forward-looking statements can be identified by the use of words such as "may," "will," "intend," " should," "could," "can," "would," "expect," "believe," "estimate," " predict," "potential," "plan," "is designed to," "target" and similar expressions. The Company assumes no obligation to update these forward-looking statements, except as required by law.